Literature DB >> 21601296

Secondary prevention in coronary artery disease. Achieved goals and possibilities for improvements.

Berglind Libungan1, Lillemor Stensdotter, Agneta Hjalmarson, Mona From Attebring, Jonny Lindqvist, Maria Bäck, Johan Herlitz.   

Abstract

AIM: To describe presence of risk indicators of recurrence 6 months after hospitalisation due to coronary artery disease at a university clinic.
METHODS: The presence of risk indicators, including tobacco use, lipid levels, blood pressure and glucometabolic status, including 24-hour blood pressure monitoring and an oral glucose-tolerance test, was analysed.
RESULTS: Of 1465 patients who were screened, 402 took part in the survey (50% previous myocardial infarction and 50% angina pectoris). Mean age was 64 years (range 40-85 years) and 23% were women. Present medications were: lipid lowering drugs (statins; 94%), beta-blockers (85%), aspirin or warfarin (100%) and ACE-inhibitors or angiotensin II blockers (66%). Values above target levels recommended in guidelines were: a) low density lipoprotein (LDL) in 40%; b) mean blood pressure (day or night) in 38% and c) smoking in 13%. Of all patients, 66% had at least one risk factor (LDL or blood pressure above target levels or current smoking). An abnormal glucose-tolerance test was found in 59% of patients without known diabetes. If no history of diabetes, 85% had either LDL or blood pressure above target levels, current smoking or an abnormal glucose-tolerance test. However, with treatment intensification to patients with elevated risk factors 56% reached target levels for blood pressure and 79% reached target levels for LDL.
CONCLUSION: Six months after hospitalisation due to coronary artery disease, despite the high use of medication aimed at prophylaxis against recurrence, the majority were either above target levels for LDL or blood pressure or continued to smoke.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21601296     DOI: 10.1016/j.ijcard.2011.04.025

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

2.  A pharmacist-led follow-up program for patients with established coronary heart disease in North Norway - a randomized controlled trial.

Authors:  Beate H Garcia; Trude Giverhaug; June U Høgli; Frode Skjold; Lars Småbrekke
Journal:  Pharm Pract (Granada)       Date:  2015-06-15

3.  Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): Protocol for a Randomized Controlled Trial Investigating Effects on Clinical Outcomes, Adherence, and Quality of Life.

Authors:  Malin Johansson Östbring; Tommy Eriksson; Göran Petersson; Lina Hellström
Journal:  JMIR Res Protoc       Date:  2018-02-20

Review 4.  Enhancing prescribing of guideline-recommended medications for ischaemic heart diseases: a systematic review and meta-analysis of interventions targeted at healthcare professionals.

Authors:  Thang Nguyen; Hoa Q Nguyen; Niken N Widyakusuma; Thao H Nguyen; Tam T Pham; Katja Taxis
Journal:  BMJ Open       Date:  2018-01-10       Impact factor: 2.692

5.  Adherence to Prescribing Guideline-Directed Medical Therapy at Hospital Discharge in Subjects With Acute Coronary Syndrome, and the Relationship With Mortality.

Authors:  Hadeel Alkofide; Raghad Alshuhayb; Nibras Alhazmi; Razan Almofada; Asmaa Bin Hazzaa; Amjad Alsharif; Hanan Abouzaid
Journal:  Cureus       Date:  2022-04-10

6.  Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): Intervention Development and Protocol for the Process Evaluation.

Authors:  Malin Johansson Östbring; Tommy Eriksson; Göran Petersson; Lina Hellström
Journal:  JMIR Res Protoc       Date:  2018-01-30

7.  Association between in-hospital guideline adherence and postdischarge major adverse outcomes of patients with acute coronary syndrome in Vietnam: a prospective cohort study.

Authors:  Thang Nguyen; Khanh K Le; Hoang T K Cao; Dao T T Tran; Linh M Ho; Trang N D Thai; Hoa T K Pham; Phong T Pham; Thao H Nguyen; Eelko Hak; Tam T Pham; Katja Taxis
Journal:  BMJ Open       Date:  2017-10-05       Impact factor: 2.692

8.  Trivial or Troublesome: Experience with Coronary Heart Disease Medication from the Patient's Perspective.

Authors:  Malin Johansson Östbring; Lina Hellström; Jan Mårtensson
Journal:  Patient Prefer Adherence       Date:  2020-02-27       Impact factor: 2.711

9.  Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial.

Authors:  Malin Johansson Östbring; Tommy Eriksson; Göran Petersson; Lina Hellström
Journal:  BMC Cardiovasc Disord       Date:  2021-08-01       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.